BOSTON, Sept. 18 /PRNewswire/ -- Scimitar Equity, LLC issues a Q4/08 review of Neurobiological Technologies, Inc. (Nasdaq: NTII), entitled, "Defining Outcome Scenarios, Probabilities Appear Focused to the Upside and Future Appreciation." This review is available at our website: http://www.scimitarequity.com
Neurobiological Technologies, Inc. (NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. NTII is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. Neurobiological Technologies, Inc. is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. For further information, please visit NTII's website at http://www.ntii.com
Scimitar Equity, LLC provides sponsored equity research of emerging
healthcare companies for the investing communities. We certify that all the
views expressed in this review, accurately reflect our personal views about
NTII (NASDAQ) and its or their securities. Investors are advised that this
analysis and review is issued solely for informational purposes and is not
to be construed as an offer to sell or the solicitation of an offer to buy.
Scimitar was paid for preparing this review. This analysis and review is
based on sources that we believe to be reliable but is not guaranteed by us
as being accurate and does not purport to be a complete statement or
summary of the available data. Any opinions expressed are statements of our
own judgment as of the date of publication and are subject to change
without notice. Please read all our important disclosures.
Scimitar Equity, LLC
Henry W. McCusker
Director of Research
phone: (617) 559.1080
|SOURCE Scimitar Equity, LLC|
Copyright©2008 PR Newswire.
All rights reserved